Virtual Physiological Human Network of Excellence

1. Virtual Physiological HumanNetwork of Excellence  VPH NoE, 2008

2. Collaborative projects within the call meet objectives associated with specific challenges VPH NoEconnects all of these projects, and must focus on addressing issues of common concern that affect VPH-I projects collectively research infrastructure training dissemination The VPH Initiative (VPH – I) Funding available: 72 M€ 12 Collaborative projects (3 IPs/9 STREPs) 2 co-ordination and support actions 1 NoE to bring these together  VPH NoE, 2008

3. VPH- I FP7 projects Parallel VPH projects Industry Grid access CA CV/ Atheroschlerosis IP Liver surgery STREP Breast cancer/ diagnosis STREP Heart/ LVD surgery STREP Osteoporosis IP Oral cancer/ BM D&T STREP Cancer STREP Networking NoE Heart /CV disease STREP Vascular/ AVF & haemodialysis STREP Liver cancer/RFA therapy STREP Alzheimer's/ BM & diagnosis STREP Heart /CV disease STREP Other Clinics Security and Privacy in VPH CA

4. VPH NoE VPH NoE - Virtual Physiological Human Network of Excellence Primary purpose to strengthen the VPH community and provide tools and services for researchers in the field Support VPH-I projects directly  VPH NoE, 2008

5. Specifically, the VPH NoE will: Identify user needs, define standards, ontologies and applications, and develop VPH ToolKit Develop VPH training activities and materials: Joint advanced degree programme, interdisciplinary study groups, focused journal issues, textbook Provide research/news dissemination services and international EU/international networking Project Coordinator: Vanessa Díaz-Zuccarini / Miriam Mendes (UCL) Scientific Coordinators: Peter Coveney (UCL), Peter Kohl (Oxford) http://www.vph-noe.eu VPH NoE

6. Consortium Overview • 13 Core Partners • 4 UK (UCL, UOXF, UNOTT, USFD) • 3 France (CNRS, INRIA, ERCIM) • 2 Spain (UPF, IMIM) • 1 Germany (EMBL [EBI]) • 1 Sweden (KI) • 1 Belgium (ULB) • 1 New Zealand (UOA) • Associate / General Members • 19 Candidate General Members • 3 Candidate Associate Members (organisations) • 5 Candidate Associate Members (industry) • 9 Associate Projects • … and growing Map of Partners

7. The VPH NoE aims to: Create a more cohesive VPH research community, both within and beyond the EU. Enhance recognition at national level of importance of modelling and simulation in biomedicine Increase Industrial and Clinical awareness of VPH modelling Increase emphasis on interdisciplinary training in biological and biomedical/engineering physics curricula Future results and impacts

8. NeoMark ICT Enabled prediction of Cancer Reoccurrence The NeoMark project will pursue the identification of imaging and genomic/ proteomic markers - from the integration of heterogeneous clinical, laboratory, molecular and imaging data - aimed at modelling recurrence of neoplastic disease with two major purposes: 1. identify subjects at higher risk of reoccurrence after reaching remission; 2. early diagnose the presence of a reoccurrence. The identification of a limited number of biomarkers, specific for the individual patient’s profile of the disease, will be used to evaluate a “lab-on-chip” test device for early identification of potential risk of relapse.  VPH NoE, 2008

9. NeoMark Baseline cohort (patients with diagnosed oral cancer) “Abnormal” Bio-profile First-line Treatment Disease bio-profile Progression or partial remission Complete remission “Normal” Bio-profile Bioprofile-assessed Reoccurrence of disease V0 V1 - Month 1 V2 - Month 3 V3 - Month 6 V4 - Month 9 V5 - Month 12 V6 - Month 15 V7 - Month 18 Treatment Follow-up Neoplastic profile Disease reoccurrence During follow-up 18-month follow-up Reappearance of “abnormal”bio-profile Remission profile Start of treatments Remission Possible Reocurrences Bioprofile-assessed Reoccurrence of disease Persistence of “normal”bio-profile Disease free at the end of follow-up  VPH NoE, 2008

10. Integrates patient’s data of different dimensions and scale to create a in-silico representation, modellingand prediction of biological phenomena linked to Oral cancer evolution Generates a multi-level and multi-scale representation of tumor biology, by integrating heterogeneous data collected with different techniques (molecular biology, imaging, clinical observation) to support clinician in predicting the risk of cancer recurrence Develops an innovative portable biomarker test device, where the most relevant (20-30) gene expressions for oral cancer relapse will be processed and will give a fast indication of individual relapse risks or of signs of cancer recurrence. Project Coordinator: Tito Poli (Azienda Ospedaliero-Universitaria di Parma Scientific Coordinator: Tito Poli (Azienda Ospedaliero-Universitaria di Parma http://www.neomark.eu NeoMark

11. NeoMark • Project coordinator: Emilia Romagna Regional Health Trust, Head Neck Department, Azienda Ospedaliero-Universitaria of Parma (I) • Contact person: Tito Poli, MD (coordinator@neomark.eu) • Partners • Fraunhofer IGD, Department Cognitive Computing & Medical Imaging, Germany • STMicroelectronics s.r.l., Italy • Fundaciòn M.D. Anderson Madrid, Spain • Link Consulting, Tecnologias e Sistemas de Informacão, S.A. Portugal • Planet A.E. , Greece • Universitad Politecnica de Madrid, Spain • MultiMed s.r.l., Italy • University of Ioannina, Research Committee, Greece  VPH NoE, 2008

12. early and more specific diagnosis of cancer recurrences; more targeted and effective interventions based on the patient-specific disease profile; avoiding unnecessary treatments for patients at very low risk of reoccurrence; optimising the work of physicians and the usage of resources; improving the scientific and medical knowledge on oral cancer processes; improve patients’ quality of life; increase the life duration for patients with cancer recurrence; availability of a real-time PCR portable diagnostic device for early detection of the “disease-bioprofile” in the long period, possible improvement of clinical guidelines and best practice for treatment of oral cancer Future results and impacts  VPH NoE, 2008